Paris

• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A trial to see if the combination of fianlimab with cemiplimab works better than pembrolizumab for preventing or delaying melanoma from com … Ended recruitment
  2022-501576-25-00 5 2023-07-07 Melanoma
• A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplante … Ended recruitment
  2022-502727-21-00 5 2023-07-03 Highly sensitised patients who have undergone kidney transplantation a
• Evaluation of Long-Term Safety and Efficacy of Apitegromab in Patients with Spinal Muscular Atrophy (a genetic condition that causes muscle … Ended recruitment
  2024-511654-42-00 5 2023-06-28 Spinal Muscular Atrophy (SMA)
• A study to test trimodulin in adult hospitalized patients with severe pneumonia Ended recruitment
  2022-501352-28-00 5 2023-06-07 Severe community-acquired pneumonia (sCAP)
• TRIO: A prospective randomized Trial of non-inferiority comparing RItuximab versus Ocrelizumab in relapsing-remitting multiple sclerosis. Ended recruitment
  2022-501027-25-01 11 2023-06-01 Multiple Sclerosis
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Ended recruitment
  2022-500929-33-01 10 2023-05-17 Human Immunodeficiency Virus (HIV-1) infection
• Phase 3 study to evaluate ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) Ended recruitment
  2023-508499-12-00 5 2023-05-17 Systemic Lupus Erythematosus
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A study to test product setrusumab in subjects with brittle bone syndrome. Ended recruitment
  2024-510919-29-00 10 2023-05-08 Osteogenesis imperfecta (OI)
• A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the … Ended recruitment
  2022-500721-32-01 4 2023-05-03 AML and MDS patients failing or being refractory to hypomethylating ag
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended recruitment
  2022-501463-40-01 5 2023-05-03 Locally Advanced or Metastatic Cholangiocarcinoma
• A Trial to Evaluate the Long-term Safety and Tolerability of TAK-861 Ended recruitment
  2023-508462-15-00 10 2023-04-27 Narcolepsy with Cataplexy (Narcolepsy Type 1)
• A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Ended recruitment
  2024-514080-25-00 5 2023-04-21 Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended recruitment
  2024-510742-13-00 5 2023-04-19 Pediatric low-grade glioma harboring an activating RAF alteration requ
• Clinical Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) versus Intravenous Pembrolizumab, Given with Chemoth … Ended recruitment
  2022-501506-36-00 5 2023-04-11 First-line treatment of participants with metastatic nonsmall cell lun
• Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended recruitment
  2022-500687-35-00 9 2023-04-04 Refractory Mantle Cell Lymphoma
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A clinical trial to investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of A … Ended recruitment
  2023-507052-69-00 4 2023-03-29 Multifocal Motor Neuropathy
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended recruitment
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A clinical trial to compare the effectiveness of savolitinib plus osimertinib versus chemotherapy for the treatment of non-small cell lung c … Ended recruitment
  2024-511169-12-00 5 2023-03-28 Non-Small Cell Lung Cancer
• Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi … Ended recruitment
  2024-512224-11-00 4 2023-03-24 Histologically confirmed frail Limited Disease Small Cell Lung Cancer
• Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended recruitment
  2023-507187-39-00 5 2023-03-23 High-Risk Non-muscle-invasive Bladder Cancer

Showing 1,465–1,488 of 2,286 trials